Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Setanaxib Capsules vs Tablets and Food Effect
NCT03740217Phase 1Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Dec 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of setanaxib in primary biliary cholangitis (PBC) (3 arms), sponsored by Calliditas Therapeutics AB. Primary endpoints: Oral Bioavailability at 72 hours and Food effect on Oral bioavailability at 72 hours. Started Dec 2018; status: completed.
02
Drugs
setanaxib
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03740217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03740217.